Literature DB >> 6144760

Quinidine-induced rise in ajmaline plasma concentration.

R Hori, K Okumura, K Inui, M Yasuhara, K Yamada, T Sakurai, C Kawai.   

Abstract

A high-performance liquid chromatographic method is described for the simultaneous determination of ajmaline and quinidine in human plasma. With 0.5 ml plasma sample of a ajmaline and quinidine, concentrations as low as 0.001 and 0.01 micrograms ml-1, respectively, could be detected and the technique could be used to investigate the effect of quinidine on the pharmacokinetics of ajmaline. Four healthy subjects were given oral ajmaline (50 mg) alone or in combination with quinidine sulphate (200 mg) on separate occasions. When ajmaline was administered alone, its plasma concentrations were less than 0.03 micrograms ml-1. Quinidine induced a marked increase to give a mean peak concentration of ajmaline which increased from 0.018 micrograms ml-1 after a single administration to 0.141 micrograms ml-1 in combination with quinidine. the area under the ajmaline concentration-time curves was increased 10 to 30-fold by the concurrent administration of quinidine. According to the one compartment open model, the absorption rate constant of ajmaline did not change appreciably, but the elimination rate constant was reduced to approximately 50% of the value in the absence of quinidine. The results indicate the existence of a significant interaction between oral ajmaline and quinidine.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6144760     DOI: 10.1111/j.2042-7158.1984.tb06942.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  9 in total

1.  Pharmacokinetics and dromotropic activity of ajmaline in rats with hyperthyroidism.

Authors:  Y Hashimoto; M Yasuhara; A Kamiya; K Okumura; R Hori
Journal:  Br J Pharmacol       Date:  1989-01       Impact factor: 8.739

2.  Single-dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizers.

Authors:  T Leemann; P Dayer; U A Meyer
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 3.  Clinical significance of genetic influences on cardiovascular drug metabolism.

Authors:  L Arcavi; N L Benowitz
Journal:  Cardiovasc Drugs Ther       Date:  1993-06       Impact factor: 3.727

4.  Metabolic disposition of ajmaline.

Authors:  C Köppel; J Tenczer; I Arndt
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1989 Oct-Dec       Impact factor: 2.441

5.  Pharmacokinetics and antiarrhythmic efficacy of intravenous ajmaline in ventricular arrhythmia of acute onset.

Authors:  C Köppel; A Wagemann; F Martens
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1989 Apr-Jun       Impact factor: 2.441

6.  Kinetics of ajmaline disposition and pharmacologic response in beagle dogs.

Authors:  M Yasuhara; Y Hashimoto; K Okumura; R Hori; T Sakurai; C Kawai
Journal:  J Pharmacokinet Biopharm       Date:  1987-02

7.  Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine.

Authors:  C J Speirs; S Murray; A R Boobis; C E Seddon; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1986-12       Impact factor: 4.335

8.  Pharmacokinetics and antiarrhythmic activity of ajmaline in rats subjected to coronary artery occlusion.

Authors:  Y Hashimoto; R Hori; K Okumura; M Yasuhara
Journal:  Br J Pharmacol       Date:  1986-05       Impact factor: 8.739

9.  Regional myocardial ajmaline concentration and antiarrhythmic activity for ischaemia- and reperfusion-induced arrhythmias in rats.

Authors:  K Okumura; Y Hashimoto; M Yasuhara; R Hori
Journal:  Br J Pharmacol       Date:  1988-04       Impact factor: 8.739

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.